Первый опыт применения рекомбинантного интерлейкина-2 отечественного производства

17 patients have been taken into this study. 15 of them had disseminated malignant melanoma. 1 had advanced colon cancer and another one multiple metastases of renal cancer in distant lymph nodes. 15 patients with malignant melanoma have been divided into three subgroups according to treatment: 1) 3 patients received high dose of RIL-2 (6 × 105-1,2×106 units) i.v. bolus injections twice a day ×3-5 days. After two days rest lymphokine-activated killer cells (LAK) have been prepared and given within 3 days. This regimen was highly toxic, whereas effect of treatment wasn't sufficient. I patient had partial remission (PR) lasted 2 weeks only. 2) 7 patients received low doses of RIL-2 (7,5 × 104 units) with LAK cells concomitantly. Toxicity of this LAK-therapy was from moderate to severe. 2 PRs have been achieved. 3) 5 patients received RIL-2 at doses of 3,5-6×105 units by means of 5 days infusion. Toxicity was mild but partial remission was only seen in one case. This study made it possible to determine patients tolerance to RIL-2. Bolus injections of 6 × 105-1,2 × 106 units of RIL-2 were highly toxic, whereas 3,5 × 105-6 × 105 units of RIL-2 given in infusion have been well tolerated.